Back to search

Article

KDM6A loss sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition

2022-07-13

Abstract excerpt

<h4>ABSTRACT</h4> Acute myeloid leukemia (AML) is a heterogeneous, aggressive malignancy with dismal prognosis and with limited availability of targeted therapies. AML exhibits epigenetic deregulation and transcriptional plasticity that contributes to pathogenesis. KDM6 proteins are histone-3 lysine-27 demethylases that play major context dependent roles in AML evolution and therapy resistance. Here, we demonstra...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ec2b97bb-032c-5c00-b15f-8522aaf2ae4d
DOI
10.1101/2022.07.12.498585
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
KDM6A loss sensitizes human acute myeloid leukemia to PARP and BCL2 inhibitionDOI 10.1101/2022.07.12.498585
KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibitionSemantic proximity
KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibitionSemantic proximity
KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemiaSemantic proximity
Loss of KDM6A confers drug resistance in acute myeloid leukemiaSemantic proximity
The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.Semantic proximity
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity
Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity
Targeting lysine demethylase 6B ameliorates ASXL1 truncation–mediated myeloid malignancies in preclinical modelsSemantic proximity
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentSemantic proximity
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged SwordSemantic proximity
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous LeukemiaSemantic proximity
Select a neighboring publication to make it the new centre.